Eventide Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Eventide Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-164,299	Closed	-$14.5M	–	157
2023 Q3	$14.5M	Hold	164,299	–	–	0.26%	103
2023 Q2	$14.2M	Hold	164,299	–	–	0.24%	104
2023 Q1	$16M	Sell	164,299 -65,701	-29%	-$6.81M	0.29%	94
2022 Q4	$23.8M	Buy	+230,000	New	+$21.6M	0.47%	69
2018 Q4	–	Sell	-132,000	Closed	-$12.8M	–	140
2018 Q3	$12.8M	Buy	132,000 +57,000	+76%	+$5.69M	0.47%	67
2018 Q2	$7.07M	Hold	75,000	–	–	0.29%	86
2018 Q1	$6.08M	Hold	75,000	–	–	0.28%	86
2017 Q4	$6.69M	Hold	75,000	–	–	0.35%	78
2017 Q3	$6.98M	Hold	75,000	–	–	0.4%	69
2017 Q2	$6.81M	Hold	75,000	–	–	0.42%	61
2017 Q1	$6.58M	Hold	75,000	–	–	0.44%	62
2016 Q4	$6.21M	Hold	75,000	–	–	0.4%	63
2016 Q3	$6.94M	Hold	75,000	–	–	0.42%	63
2016 Q2	$5.83M	Hold	75,000	–	–	0.36%	68
2016 Q1	$6.19M	Hold	75,000	–	–	0.35%	67
2015 Q4	$7.86M	Sell	75,000 -5,400	-7%	-$564K	0.39%	65
2015 Q3	$8.47M	Buy	80,400 +28,600	+55%	+$3.82M	0.49%	58
2015 Q2	$7.08M	Buy	51,800 +11,700	+29%	+$1.45M	0.38%	65
2015 Q1	$5M	Buy	40,100 +9,900	+33%	+$1.05M	0.38%	69
2014 Q4	$2.73M	Hold	30,200	–	–	0.3%	70
2014 Q3	$2.18M	Hold	30,200	–	–	0.3%	69
2014 Q2	$1.88M	Buy	30,200 +2,100	+7%	+$127K	0.26%	78
2014 Q1	$1.92M	Buy	28,100 +17,700	+170%	+$1.3M	0.3%	70
2013 Q4	$731K	Buy	+10,400	New	+$706K	0.23%	68

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Eventide Asset Management's BMRN Position: Q4 2023 in Review

Eventide Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 164,299 shares — an estimated $14.5M sold.

Eventide Asset Management first reported a position in BMRN in Q4 2013 and held it in 24 quarters. The position peaked at $23.8M in Q4 2022. 548 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

Eventide Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Eventide Asset Management sold 164,299 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $14.5M.
Eventide Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 24 quarters.
Eventide Asset Management's BioMarin Pharmaceuticals position peaked at $23.8M in Q4 2022.
548 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Eventide Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.